Survey on long-term use of fostamatinib for chronic idiopathic thrombocytopenic purpura
Special Drug Use-results Survey for Long-term Use (Fostamatinib)
This study is looking to see how well and safely fostamatinib works for Japanese patients with chronic idiopathic thrombocytopenic purpura who are using it for the first time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 149 (estimated) |
| Sex | All |
| Sponsor | Kissei Pharmaceutical Co., Ltd. Industry-sponsored |
| Drugs / interventions | fostamatinib |
| Locations | 1 site (Tokyo and Japanese Other Cities) |
| Trial ID | NCT06757257 on ClinicalTrials.gov |
What this trial studies
This survey evaluates the safety and efficacy of fostamatinib in Japanese patients diagnosed with chronic idiopathic thrombocytopenic purpura who are using the medication for the first time. The study is observational, meaning it will gather data on patients' experiences and outcomes under real-world conditions rather than in a controlled experimental setting. The focus is on understanding how well the drug works and its safety profile over an extended period.
Who should consider this trial
Good fit: Ideal candidates for this survey are Japanese patients who have been diagnosed with chronic idiopathic thrombocytopenic purpura and are starting treatment with fostamatinib for the first time.
Not a fit: Patients who have previously used fostamatinib or those with other forms of thrombocytopenia may not benefit from this survey.
Why it matters
Potential benefit: If successful, this survey could provide valuable insights into the long-term safety and effectiveness of fostamatinib, potentially improving treatment strategies for patients with chronic idiopathic thrombocytopenic purpura.
How similar studies have performed: While this approach is observational and focuses on long-term use, similar studies evaluating the safety and efficacy of treatments in real-world settings have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.
Where this trial is running
Tokyo and Japanese Other Cities
- Research site — Tokyo and Japanese Other Cities, Japan (Recruiting)
Study contacts
- Study coordinator: Kazunori Abe, director
- Email: rinsyousiken@pharm.kissei.co.jp
- Phone: 0356843575
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.